These innovative molecules represent a significant progression in the therapy of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates promising efficacy in reducing blood glucose levels. https://jonasjcou966553.mybloglicious.com/59008442/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide